Telemetry Investments’s Five Prime Therapeutics, Inc. FPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-8,697
| Closed | -$328K | – | 191 |
|
|
2021
Q1 | $328K | Buy |
+8,697
| New | +$217K | 0.37% | 87 |
|
|
2018
Q2 | – | Sell |
-46,500
| Closed | -$799K | – | 170 |
|
|
2018
Q1 | $799K | Buy |
46,500
+2,324
| +5% | +$45.3K | 0.3% | 60 |
|
|
2017
Q4 | $968K | Buy |
44,176
+34,176
| +342% | +$1.1M | 0.37% | 48 |
|
|
2017
Q3 | $409K | Sell |
10,000
-22,851
| -70% | -$717K | 0.15% | 81 |
|
|
2017
Q2 | $989K | Buy |
32,851
+5,651
| +21% | +$176K | 0.47% | 44 |
|
|
2017
Q1 | $983K | Buy |
+27,200
| New | +$1.2M | 0.44% | 38 |
|
|
2016
Q4 | – | Sell |
-7,000
| Closed | -$367K | – | 126 |
|
|
2016
Q3 | $367K | Sell |
7,000
-19,000
| -73% | -$907K | 0.23% | 59 |
|
|
2016
Q2 | $1.07M | Sell |
26,000
-500
| -2% | -$21.7K | 0.58% | 34 |
|
|
2016
Q1 | $1.08M | Buy |
26,500
+8,000
| +43% | +$275K | 0.31% | 41 |
|
|
2015
Q4 | $768K | Sell |
18,500
-84,000
| -82% | -$2.82M | 0.26% | 59 |
|
|
2015
Q3 | $1.58M | Buy |
102,500
+61,500
| +150% | +$1.32M | 0.68% | 43 |
|
|
2015
Q2 | $1.02M | Buy |
41,000
+26,000
| +173% | +$579K | 0.46% | 50 |
|
|
2015
Q1 | $343K | Buy |
+15,000
| New | +$379K | 0.19% | 107 |
|
Telemetry Investments's FPRX Position: Q2 2021 in Review
Telemetry Investments sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 8,697 shares — an estimated $328K sold.
Telemetry Investments first reported a position in FPRX in Q1 2015 and held it in 13 quarters. The position peaked at $1.58M in Q3 2015. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.
- Telemetry Investments reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
- Telemetry Investments sold 8,697 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $328K.
- Telemetry Investments first reported a position in Five Prime Therapeutics, Inc. in Q1 2015 and held it in 13 quarters.
- Telemetry Investments's Five Prime Therapeutics, Inc. position peaked at $1.58M in Q3 2015.
- 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.
Based on Telemetry Investments's 13F filing for Q2 2021, filed 16 Aug 2021.